SNP318
Asset
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 4
- Indications
- 2
- Trials
- 1
- Developer
Trial NCT07199777 is still running. Trial NCT07199777 started on Nov 1, 2025. clinicaltrials.gov
Indications
4Diabetic macular edema
Phase 2, Not yet recruiting, NCT07199777, clinicaltrials.gov, Oct 31, 2026
DME
Phase 2, Not yet recruiting, NCT07199777, clinicaltrials.gov, Oct 31, 2026
Alzheimer's disease
Phase 1, Completed, NCT05792163, clinicaltrials.gov, Nov 13, 2026
1 more
In the full profile
- Owner and partners1
- Trials2
- Competitors12
Every asset’s record: target, stage, trials and the evidence behind it.